Form 4: Align Technology CFO Plans Future Stock Sale

Align Technology's EVP and CFO, John Morici, has reported a scheduled sale of 7,969 shares of common stock under a pre-arranged trading plan.

Summary

• John Morici, Executive Vice President and Chief Financial Officer of Align Technology, Inc. (ALGN), has filed a Form 4 disclosing a planned transaction.
• The filing reports a scheduled sale of 7,969 shares of Align Technology common stock.
• The transaction is slated to occur on February 18, 2026, at an average price of $189.3143 per share.
• The shares are expected to be sold in multiple transactions within a price range of $189.050 to $189.65.
• This planned sale is being conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following this scheduled transaction, Mr. Morici is expected to beneficially own 8,237 shares of common stock directly.
• The reported beneficial ownership includes 183 shares acquired on January 30, 2026, under the ALGN Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it's a planned insider sale, the 10b5-1 plan mitigates negative implications, and the executive's remaining holdings indicate continued alignment with shareholder interests.

Positives

• The reported sale is scheduled to occur under a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction for personal financial management rather than a reaction to new, non-public information.
• Mr. Morici acquired 183 shares through the Employee Stock Purchase Plan on January 30, 2026, demonstrating continued participation in employee ownership programs.

Negatives

• The filing indicates a planned reduction in direct beneficial ownership by a key executive, with 7,969 shares of common stock scheduled for sale.

Risks

• The market might misinterpret the planned insider sale as a lack of confidence, despite the disclosure of a Rule 10b5-1 plan.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that insider sales, particularly those pre-arranged under Rule 10b5-1 plans, are a common practice for executives managing personal finances, diversifying portfolios, or exercising vested equity. This disclosure by Align Technology's CFO is a routine transparency measure for executive compensation and stock ownership within the medical device and dental technology sector.

Comparison to Industry Standards

• Insider selling under a Rule 10b5-1 plan is a standard practice for executives across various industries, including healthcare and technology, to manage personal liquidity and diversification while adhering to insider trading regulations.
• The use of a 10b5-1 plan aligns with best corporate governance practices, similar to those observed at peer companies like Dentsply Sirona (XRAY) or Henry Schein (HSIC), where executives periodically monetize vested equity in a pre-scheduled manner.

Stakeholder Impact

• Shareholders: The disclosure of a planned future sale by a key executive, even under a 10b5-1 plan, could lead to minor speculation, though the pre-arranged nature typically mitigates significant negative impact.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The filing reports a routine, pre-arranged insider sale by the CFO under a Rule 10b5-1 plan. This type of transaction is typically for personal financial management and does not inherently signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this disclosure. The executive still retains a significant number of shares.

Keywords

ALGN, Align Technology, insider trading, Form 4, stock sale, John Morici, CFO, 10b5-1 plan, common stock